The Polynucleotide Is Encapsidated Within A Virus Or Viral Coat Patents (Class 435/456)
  • Patent number: 12116385
    Abstract: The disclosure is directed in part to variant capsid polypeptides that can be used to deliver payloads.
    Type: Grant
    Filed: May 24, 2023
    Date of Patent: October 15, 2024
    Assignee: DYNO THERAPEUTICS, INC.
    Inventors: Ina Chen, Jeff Gerold, Jerrah Holth, Sylvain Lapan, Kathy S. Lin, Samuel Wolock
  • Patent number: 12098384
    Abstract: The present invention relates to a novel adenoviral vector not including a replication competent adenovirus. A recombinant E1/E3/E4-deleted adenoviral vector, of the present invention, in which an antigenic protein and an E4orf6 gene are inserted in an E1 gene-deleted region, has adenovirus productivity, degree of antigen expression, neutralizing antibody production amount, and T cell induction ability that are similar to those of a control group, and thus can be effectively used as a carrier for various vaccines for diseases or anti-cancer vaccines.
    Type: Grant
    Filed: January 20, 2022
    Date of Patent: September 24, 2024
    Assignee: Cellid Co., Ltd.
    Inventors: Chang-Yuil Kang, Bongju Park, Kwang-Soo Shin, Tae-Gwon Oh
  • Patent number: 12100144
    Abstract: A method for assisting in cell isolation from a biological tissue section includes: obtaining cell images that are each an image of cells isolated from the biological tissue section, the biological tissue section being soaked in a solution containing an enzyme; calculating, from the cell images, a number of the cells isolated from the biological tissue section as an indicator of the cell isolation from the biological tissue section; and visualizing a temporal change in the indicator on the basis of a history of the indicator.
    Type: Grant
    Filed: February 10, 2022
    Date of Patent: September 24, 2024
    Assignee: Evident Corporation
    Inventors: Akira Matsushita, Yu Hirosawa, Taiji Mine
  • Patent number: 12091668
    Abstract: Disclosed are systems and methods that include or utilize composable mammalian elements of transcription (COMET) including engineered recombinant proteins that regulate transcription and engineered DNA promoter sequences that are regulated by the engineered recombinant proteins. The elements may be composed to form logic gates, gene expression cascades and programs, and cell-based biosensors.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: September 17, 2024
    Assignee: Northwestern University
    Inventors: Joshua N. Leonard, Patrick S. Donahue
  • Patent number: 12061188
    Abstract: Compositions of retroviruses and methods of using the same for gene delivery, wherein the retroviruses comprise a viral envelope protein comprising at least one mutation that diminishes its native function, a non-viral membrane-bound protein comprising a membrane-bound domain and an extracellular targeting domain.
    Type: Grant
    Filed: August 30, 2023
    Date of Patent: August 13, 2024
    Assignee: Massachusetts Institute of Technology
    Inventors: Michael Birnbaum, Connor Dobson
  • Patent number: 12053518
    Abstract: The present invention relates to methods of rescue and/or propagation of paramyxovirus species, particularly wherein both rescue and propagation are carried out in the same cell type; i.e., without the use of helper cells for viral rescue. The paramyxoviruses produced by the disclosed methods may encompass wild-type viruses, chimeric viruses, recombinant viruses or engineered viral products such as virus like particles (VLP). Viruses and/or viral products produced in the method according to the current invention are suitable for medical or veterinary use in such applications as treating or preventing infectious diseases, particularly avian paramyxovirus and human respiratory virus infections, and cancer treatment.
    Type: Grant
    Filed: July 15, 2019
    Date of Patent: August 6, 2024
    Assignee: Valneva SE
    Inventors: Luc Batard, Caroline Freslon-Evain, Fabien Perugi, Klaus Schwamborn
  • Patent number: 12043823
    Abstract: Implementations are described that relate to methods and systems for growing cells in a hollow fiber bioreactor. In implementations, the cells may be exposed to a number of growth factors including a combination of recombinant growth factors. In other implementations, the cells may be grown in co-culture with other cells, e.g., hMSC's. In implementations, the cells may include CD34+ cells. A coated membrane includes a membrane having a first coating configured to promote cellular adhesion to the membrane and a second coating that includes a soluble protein moiety.
    Type: Grant
    Filed: March 23, 2022
    Date of Patent: July 23, 2024
    Assignee: Terumo BCT, Inc.
    Inventors: Mark E. Jones, Dalip Sethi, Dennis J. Hlavinka, Thomas J. Felt
  • Patent number: 11969478
    Abstract: The present invention relates to the prevention and/or treatment of retinal dystrophy in a patient, including Leber congenital amaurosis (LCA).
    Type: Grant
    Filed: February 20, 2020
    Date of Patent: April 30, 2024
    Assignee: UCL BUSINESS LTD.
    Inventors: Alexander Smith, Robin Ali
  • Patent number: 11957715
    Abstract: The present invention discloses an in-vitro method for transferring biological material into activated NK cells with a pseudotyped retroviral vector particle or a virus-like particle thereof, comprising the steps a) activation of NK cells, and b) addition of said pseudotyped retroviral vector particle or virus-like particle thereof to said activated NK cells, wherein said pseudotyped retroviral vector particle or virus-like particle thereof comprises a modified baboon endogenous retrovirus (BaEV) envelope glycoprotein that is able of binding to and fusing with a hematopoietic cell membrane, thereby transferring biological material into said activated NK cells. Preferentially, the activating of NK cells is performed by the addition of a IL-1 family cytokine to the NK cells.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: April 16, 2024
    Assignee: MILTENYI BIOTEC B.V. & CO. KG
    Inventors: Rafijul Bari, Markus Granzin, Wing Leung, Nina Moker, Volker Huppert
  • Patent number: 11957762
    Abstract: Disclosed herein, are recombinant polypeptides comprising one or more homologous amino acid repeats; and, non-immunogenic bioconjugates comprising recombinant polypeptides comprising one or more homologous amino acid repeats and one or more therapeutic agents. Also, disclosed herein are pharmaceutical compositions including the recombinant polypeptides; and methods of administering the recombinant polypeptides to patients for the treatment of cancer or infections.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: April 16, 2024
    Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATION
    Inventors: Mingnan Chen, Hyung Jin Cho, Peng Wang, Shuyun Dong, Peng Zhao
  • Patent number: 11951141
    Abstract: Disclosed are replication-enhanced oncolytic adenoviruses. These oncolytic adenoviruses have tumor-specific replication capable of enhanced tumor oncolysis and enhanced therapeutic transgene expression. Also disclosed are methods comprising administering a replication-enhanced oncolytic adenovirus for patients suffering from a cancer.
    Type: Grant
    Filed: November 6, 2020
    Date of Patent: April 9, 2024
    Assignees: MEMGEN, INC., H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
    Inventors: Mark J. Cantwell, Amer A. Beg
  • Patent number: 11896651
    Abstract: Provided herein are compositions, methods, kits, and viral particles for treating a disease or disorder associated with a deep intronic mutation using an engineered, non-naturally occurring Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-CRISPR associated (Cas) (CRISPR-Cas) system. In some aspects, provided herein is a self-limiting CRISPER-Cas system.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: February 13, 2024
    Assignee: GENZYME CORPORATION
    Inventors: Guoxiang Ruan, Abraham Scaria
  • Patent number: 11882815
    Abstract: The disclosure, in some aspects, relates to methods and compositions for recombinant adeno-associated virus (rAAV)-mediated delivery of genome editing molecules to a pre-implantation embryo.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: January 30, 2024
    Assignee: University of Massachusetts
    Inventors: Jaime Antonio Rivera-Perez, Guangping Gao
  • Patent number: 11859199
    Abstract: An adenoviral vector comprising two expression cassettes, wherein each expression cassette comprises a transgene and a promoter, and wherein each transgene encodes an RSV antigenic protein or a fragment thereof.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: January 2, 2024
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventor: Stefano Colloca
  • Patent number: 11851671
    Abstract: Compositions providing, and methods for providing and using, targeted rAAV are disclosed.
    Type: Grant
    Filed: October 23, 2018
    Date of Patent: December 26, 2023
    Assignee: Regents of the University of Minnesota
    Inventors: Daniel Schmidt, Wendy Gordon, Alina Catherine Zdechlik
  • Patent number: 11851463
    Abstract: The present disclosure provides immunogenic compositions, such as vaccines, including DNA vaccines, and uses thereof, e.g., which include an annexin core domain to mediate efficient antigen delivery and antigen presentation in order to induce an antigen-specific immune response and/or to treat or prevent infectious diseases and/or cancer.
    Type: Grant
    Filed: January 21, 2021
    Date of Patent: December 26, 2023
    Assignee: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS
    Inventors: Fatmire Bujupi, Peter Krammer, Heiko Weyd
  • Patent number: 11834474
    Abstract: The invention in some aspects relates to recombinant adeno-associated viruses having distinct tissue targeting capabilities. In some aspects, the invention relates to gene transfer methods using the recombinant adeno-associate viruses. In some aspects, the invention relates to isolated AAV capsid proteins and isolated nucleic acids encoding the same.
    Type: Grant
    Filed: May 8, 2020
    Date of Patent: December 5, 2023
    Assignee: University of Massachusetts
    Inventors: Guangping Gao, Terence Flotte, Jun Xie
  • Patent number: 11814674
    Abstract: Methods for the rapid amplification of extremely low quantity nucleic acids in a sample are provided. The disclosed methods are capable of amplifying less than 1 pg of DNA and/or RNA from a biological sample using a single tube and one-step or two-step preparation.
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: November 14, 2023
    Assignee: The United States of America, as represented by the Secretary Department of Health and Human Services
    Inventor: Fei Fan Ng
  • Patent number: 11788091
    Abstract: Provided herein is a previously unannotated lncRNA lying within exon six and 3?UTR of the LCK gene, labeled “HULLK” for Hormone-Upregulated lncRNA within LCK. HULLK is a novel lncRNA situated within the LCK gene that can serve as an oncogene in PCa. Accordingly, provided are methods and compositions for diagnosing and treating prostate cancer based on HULLK that regulates prostate cancer cell growth.
    Type: Grant
    Filed: August 21, 2020
    Date of Patent: October 17, 2023
    Assignee: University of Virginia Patent Foundation
    Inventor: Daniel G. Gioeli
  • Patent number: 11788088
    Abstract: A CRISPR/Cas system and method for editing or regulating transcription of a genome of a cell are provided, wherein the system includes a Cas endonuclease fused with one or more degron sequences and at least one activatable cognate single guide RNA harboring an inactivation sequence in a non-essential region of the cognate sgRNA, wherein said inactivation sequence comprises one or more endonuclease recognition sites of, e.g., a ribozyme.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: October 17, 2023
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Ryan E. Clarke, Bradley J. Merrill, Matthew S. MacDougall, Hannah M. Pennington, Brian R. Shy
  • Patent number: 11779656
    Abstract: Compositions and regimens useful in treating hemophilia A are provided. The compositions include recombinant adeno-associated virus (rAAV) with a transthyretin enhancer and promoter driving expression of a human Factor VIII.
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: October 10, 2023
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Lili Wang, James M. Wilson, Jenny Agnes Sidrane
  • Patent number: 11779655
    Abstract: The present disclosure generally relates to polynucleotides and AAV vectors that provide for the expression of ALD protein in target (e.g., neurons or glial) cells when administered to subjects in need thereof. The present disclosure further relates to compositions comprising such a polynucleotide or vector. These polynucleotides, vectors, and compositions may be used for the treatment and prevention of ALD or AMN in subjects in need thereof.
    Type: Grant
    Filed: December 21, 2021
    Date of Patent: October 10, 2023
    Assignee: SwanBio Therapeutics Limited
    Inventors: Sean Clark, Karen Kozarsky, Tugba Guven-Ozkan, Anna Tretiakova
  • Patent number: 11767346
    Abstract: Adeno associated viral (AAV) particles are emerging as a useful vehicle for gene delivery to various organs and tissues, one of them being the retina. Provided here are variant AAV (for example, variant serotype 2 (AAV2)) capsid proteins and variant capsid protein containing particles with enhanced ability to transduce retinal cells.
    Type: Grant
    Filed: March 8, 2022
    Date of Patent: September 26, 2023
    Assignees: University of Florida Research Foundation, Incorporated, The UAB Research Foundation
    Inventors: Sergei Zolotukhin, Sanford L. Boye, Shannon E. Boye, Damien Marsic, Paul D. Gamlin
  • Patent number: 11767540
    Abstract: In a first aspect, the present invention relates to a mutated adeno-associated virus (AAV) capsid protein or fragment thereof wherein a substitution of a wild type non-cysteine amino acid into a cysteine is present whereby the wild type non-cysteine amino acid is exposed on the outer surface of the capsid of an AAV particle. In a further aspect, a mutated AAV particle comprising the AAV capsid protein or fragment thereof according to the present invention is provided. In addition, a nucleic acid encoding the AAV capsid protein according to the present invention is identified together with a corresponding nucleic acid vector, in particular, a plasmid or a gene string. In addition, a host cell containing the nucleic acid vector or the nucleic acid according to the present invention as well as a composition comprising at least an infectious (transducing) AAV particle containing a mutated AAV capsid protein as defined herein together with a non-infectious AAV particle containing a mutated AAV capsid protein as e.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: September 26, 2023
    Assignee: FRAUNHOFER-GESELLSCHAFT ZUR FORDERUNG DER ANGEW ANDTEN FORSCHUNG E.V.
    Inventors: Hildegard Büning, Anke Huber, Luca Perabo
  • Patent number: 11732246
    Abstract: Viral vectors comprising engineered hOTC DNA and RNA sequences are provided which when delivered to a subject in need thereof are useful for treating hyperammonemia, ornithine transcarbamylase deficiency and symptoms associated therewith. Also provided are methods of using hOTC for treatment of liver fibrosis and/or cirrhosis in OTCD patients by administering hOTC.
    Type: Grant
    Filed: August 17, 2020
    Date of Patent: August 22, 2023
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Lili Wang, James M. Wilson
  • Patent number: 11702674
    Abstract: The present invention relates to isolated polynucleotide and polypeptide sequences derived from novel chimpanzee adenovirus ChAd157, as well as to recombinant polynucleotides, vectors, adenoviruses, cells and compositions comprising said polynucleotide and polypeptide sequences.
    Type: Grant
    Filed: June 11, 2019
    Date of Patent: July 18, 2023
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Virginia Ammendola, Stefania Capone, Stefano Colloca, Antonella Folgori, Rossella Merone
  • Patent number: 11696949
    Abstract: The present invention provides a method for preparing a coronavirus-targeting universal DC cell vaccine, and belongs to the technical field of virus vaccine preparation. The preparation method includes the following steps: ligating a fusion gene including a HLA gene and a coronavirus antigen gene onto an expression vector to obtain a recombinant vector; then transferring the recombinant vector into antigen-presenting cells to be transfected to obtain the coronavirus-targeting universal DC cell vaccine. The universal DC cell vaccine of the present invention has a targeting property against a coronavirus, can effectively stimulate a CTL, and has a killing effect on a target cell.
    Type: Grant
    Filed: August 10, 2020
    Date of Patent: July 11, 2023
    Assignees: Beijing DCTY Biotech Co., Ltd.
    Inventors: Shunchang Jiao, Rong Zhang, Zishan Zhou
  • Patent number: 11680249
    Abstract: The present disclosure provides recombinant adeno-associated virus virions with variant capsid protein, where the recombinant AAV (rAAV) virions exhibit one or more of increased ability to cross neuronal cell barriers, increased infectivity of a neural stem cell, increased infectivity of a neuronal cell, and reduced susceptibility to antibody neutralization, compared to a control AAV, and where the rAAV virions comprise a heterologous nucleic acid. The present disclosure provides methods of delivering a gene product to a neural stem cell or a neuronal cell in an individual. The present disclosure also provides methods of modifying a target nucleic acid present in a neural stem cell or neuronal cell.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: June 20, 2023
    Assignee: The Regents of the University of California
    Inventors: David V. Schaffer, David Stephen Ojala, Philip A. Romero
  • Patent number: 11653636
    Abstract: The present invention relates to a Pde6b-deficient animal model of retinal degeneration produced by engineered endonucleases, and a method for producing the same. In the animal model of retinal degeneration according to the present invention, only a specific target gene can be removed using engineered endonucleases, so that mutagenesis can be stably achieved. In addition, it is possible to produce a congenital animal model through genetic manipulation at the embryonic stage rather than through acquired factors, which allows for production of an animal model that uniformly exhibits symptoms of the disease in question without being influenced by other factors.
    Type: Grant
    Filed: November 15, 2019
    Date of Patent: May 23, 2023
    Assignees: UNIVERSITY OF ULSAN FOUNDATION FOR INDUSTRY COOPERATION, THE ASAN FOUNDATION
    Inventors: Joo Yong Lee, In Jeoung Baek, Young Hoon Sung
  • Patent number: 11649467
    Abstract: The invention provides adenoviral vectors comprising transgenes encoding Chikungunya virus antigens. The vectors can be used to produce vaccines for the prophylaxis, amelioration and treatment of diseases caused by Chikungunya virus infections.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: May 16, 2023
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Benjamin Wizel, Martine Harvey, Lucile Warter, Kate Luisi
  • Patent number: 11629342
    Abstract: The present disclosure provides methods and compositions of modulating expression of a target nucleic acid in a eukaryotic cell. The methods include providing to the cell a guide RNA complementary to the target nucleic acid sequence, providing to the cell a fusion protein, wherein the fusion protein comprises a nuclease null Cas9 protein and a transcriptional effector domain, wherein the nuclease null Cas9 protein interacts with the guide RNA and binds to the target nucleic acid sequence in a site specific manner and wherein the transcriptional effector domain modulates expression of the target nucleic acid.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: April 18, 2023
    Assignee: President and Fellows of Harvard College
    Inventors: Alejandro Chavez, Nan Cher Yeo
  • Patent number: 11591579
    Abstract: Disclosed herein are compositions related to conjugated polypeptides with MTA/ADO-degrading enzyme activity. The conjugated polypeptides are engineered to allow for maximal conjugation while maintaining catalytic activities. Also disclosed are nucleic acids, expression vectors, and host cells related to the conjugated polypeptides. Further disclosed are methods of using the pharmaceutical formulations comprising above to treat cancer.
    Type: Grant
    Filed: November 1, 2021
    Date of Patent: February 28, 2023
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventor: Everett Stone
  • Patent number: 11584908
    Abstract: A device for treatment of cells with particles is disclosed. The device includes a semi-permeable membrane positioned between two plates, the first plate defining a first flow chamber and comprising a port, a flow channel, a transverse port, and a transverse flow channel, the first flow chamber constructed and arranged to deliver fluid in a transverse direction along the first side of the semi-permeable membrane, the second plate defining a second flow chamber and comprising a port. A method for transducing cells is disclosed. The method includes introducing a fluid with cells and viral particles into a flow chamber adjacent a semi-permeable membrane such that the cells and the viral particles are substantially evenly distributed on the semi-permeable membrane. The method also includes introducing a recovery fluid to suspend the cells and the viral particles, and separating the cells from the viral particles. A method of activating cells is disclosed.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: February 21, 2023
    Assignee: THE CHARLES STARK DRAPER LABORATORY, INC.
    Inventors: Kenneth T. Kotz, Bryan D. Teece, James Gillett Truslow, Nathan Francis Moore, Jeffrey T. Borenstein, Vishal Tandon
  • Patent number: 11524988
    Abstract: Disclosed herein are methods of producing chimeric antigen receptor (CAR) T cells using substrates, such as artificial antigen presenting cells, containing on a surface a a heparin binding domain (HBD), anti-CD3 single chain antibodies, anti-CD28 single chain antibodies (scFv), and optionally anti-41BBL antibodies. Anti-CD3 and Anti-CD28 scFvs bind and activate expanding T cells ex vivo, while the Heparin Binding Domain binds the viral vector, thereby bringing the T cells into close proximity with virus for effective gene transfer. This is a less costly, renewable, modifiable, and efficacious alternative to coated beads and RetroNectin® for gene transfer.
    Type: Grant
    Filed: September 19, 2017
    Date of Patent: December 13, 2022
    Assignee: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
    Inventor: Marco Davila
  • Patent number: 11499137
    Abstract: Described herein are methods and related compositions for inducing differentiation of human pluripotent stem cells (hPSCs) into hemogenic endothelium with pan-myeloid potential or restricted potential, by forced expression in the hPSCs of a combination of transcription factors as described herein.
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: November 15, 2022
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Igor Slukvin, Irina Elcheva
  • Patent number: 11421248
    Abstract: The present disclosure relates to methods for transiently activating temperature-sensitive agents in one or more cells, for example by contacting one or more cells with a temperature-sensitive agent and transiently incubating the cells at a permissive temperature for inducing an activity of the temperature-sensitive agent in the cells. Additionally, the present disclosure relates to methods of contacting one or more cells in a subject with a temperature-sensitive agent and then lowering the subject's core body temperature to a permissive temperature for inducing an activity of the temperature-sensitive agent in the cells. The disclosure also relates to methods of contacting one or more cells in a subject with a temperature-sensitive agent, maintaining the subject's surface body temperature at a permissive temperature for inducing an activity of the temperature-sensitive agent in the cells. Further disclosed are methods of treating a subject with a temperature-sensitive therapeutic agent.
    Type: Grant
    Filed: August 17, 2021
    Date of Patent: August 23, 2022
    Assignee: Elixirgen Therapeutics, Inc.
    Inventor: Minoru S. H. Ko
  • Patent number: 11419897
    Abstract: The present invention provides a clinically applicable method of stem cell transplantation that facilitates engraftment and reconstitutes immunocompetence of the recipient without requiring radiotherapy or chemotherapy, and without development of GVHD or graft rejection. Aspects of the present invention are based on the discovery that the depletion of the endogenous stem cell niche facilitates efficient engraftment of stem cells into that niche. In particular, the present invention combines the use of selective ablation of endogenous stem cells with a combination of antibodies specific for CD117, and agents that modulate immunoregulatory signaling pathways, e.g. agonists of immune costimulatory molecules, in combination with the administration to the recipient of exogenous stem cells, resulting in efficient, long-term engraftment, even in immunocompetent recipients.
    Type: Grant
    Filed: July 30, 2019
    Date of Patent: August 23, 2022
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Judith A. Shizuru, Irving L. Weissman, Kipp Andrew Weiskopf, Aaron Michael Ring, Akanksha Chhabra, Peter Schnorr
  • Patent number: 11413310
    Abstract: Provided are adoptive cell therapy methods involving the administration of doses of cells for treating disease and conditions, including certain B cell malignancies. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the methods are for treating subjects with non-Hodgkin lymphoma (NHL). In some embodiments, the methods are for treating subjects with relapsed or refractory NHL. Also provided are articles of manufacture and prophylactic treatments in connection with adoptive therapy methods.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: August 16, 2022
    Assignee: Juno Therapeutics, Inc.
    Inventors: Tina Albertson, Brian Christin, Jacob Randolph Garcia, Christopher Glen Ramsborg, Claire L. Sutherland, Clinton Weber, Rachel K. Yost, Mark J. Gilbert, He Li
  • Patent number: 11395836
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating cancer comprising cancer antigen-specific cytotoxic T cells; the pharmaceutical composition comprises about 7×106 cells/mL or more, and of the about 7×106 cells/mL, about 90% or more are CD8+ T cells.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: July 26, 2022
    Assignee: Eutilex Co., Ltd.
    Inventors: Byoung S. Kwon, Young Ho Kim, Mun Ki Kim, Kwang Hee Kim, You Hyun Kang
  • Patent number: 11352607
    Abstract: Provided are methods and compositions for obtaining genome-engineered iPSCs, and derivative cells with stable and functional genome editing at selected sites. Also provided are cell populations or clonal cell lines derived from genome-engineered iPSCs, which comprise targeted integration of one or more exogenous polynucleotides, and/or in/dels in one or more selected endogenous genes.
    Type: Grant
    Filed: October 17, 2019
    Date of Patent: June 7, 2022
    Assignee: Fate Therapeutics, Inc.
    Inventors: Bahram Valamehr, Ramzey Abujarour, Tom Tong Lee, Weijie Lan, Raedun Clarke, Ryan Bjordahl
  • Patent number: 11305022
    Abstract: The invention provides methods for treating neurological disorders, which involve administering therapeutic agents to the thalamus by convection enhanced delivery.
    Type: Grant
    Filed: January 29, 2010
    Date of Patent: April 19, 2022
    Assignee: The Regents of the University of California
    Inventors: Krystof Bankiewicz, Adrian P. Kells
  • Patent number: 11207425
    Abstract: A gRNA molecule includes a first domain complementary to at least a portion of TCOF1 gene, and a second domain for binding with Cas9 protein, and a kit includes the gRNA molecule. A method of treating a subject suffering from a cancer associated with an elevated expression of TCOF1 gene includes the step of administering an effective amount of a first recombinant vector comprising the gRNA molecule of the invention to the subject. A method of inhibiting the expression of TCOF1 gene in cancer cells associated with an elevated expression of TCOF1 gene includes contacting the cancer cells with a first recombinant vector, wherein the first recombinant vector comprises a gRNA molecule comprising a first domain complementary to at least a portion of TCOF1 gene and a second domain binding with Cas9 protein.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: December 28, 2021
    Assignee: City University of Hong Kong
    Inventors: Yuet Ming Rebecca Chin, Xin Wang, Jianyang Hu
  • Patent number: 11149255
    Abstract: Provided herein are methods for generating reversion free attenuated and/or replication incompetent vaccine vectors and their use in vaccine compositions and vaccination. In particular, the use of a codon shuffled helper gene is used to produce compositions comprising replication incompetent virus.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: October 19, 2021
    Assignees: BioVentures, LLC, The Research Foundation for the State of University of New York
    Inventors: James Forrest, Gang Li, Laurie Krug, Steven Skiena
  • Patent number: 11136554
    Abstract: The present invention provides methods of reprogramming cells, for example, directly reprogramming a somatic cell of a first cell type into a somatic cell of a second cell type, are described herein. In particular, the present invention generally relates to methods for reprogramming a cell of an endoderm origin to a cell having pancreatic ?-cell characteristics. The present invention also relates to an isolated population comprising reprogrammed cells, compositions and their use in the treatment of diabetes mellitus. In particular, the present invention relates to reprogramming a cell of an endoderm origin to a cell having pancreatic ?-cell characteristics by increasing the protein expression of at least one transcription factor selected from Pdx1, Ngn3 or MafA in the cell of endoderm origin to reprogram the cell of an endoderm cell to a cell which exhibits at least one or at least two characteristics of an endogenous pancreatic ?-cell.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: October 5, 2021
    Assignee: President and Fellows of Harvard College
    Inventors: Douglas A. Melton, Qiao Zhou
  • Patent number: 11098325
    Abstract: Genetically modified compositions, such as adeno-associated viral vectors and primary cells, for treating various conditions and diseases. Disclosed are also modified adeno-associated viruses for the treatment of cancer. Also disclosed are the methods of making and using the genetically modified compositions in treating various diseases, conditions, and cancer.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: August 24, 2021
    Assignee: INTIMA BIOSCIENCE, INC.
    Inventors: Thomas Henley, Mavis Agbandje-McKenna, Tilmann Buerckstuemmer, Lydia Viney, Modassir Choudhry
  • Patent number: 10981969
    Abstract: The present invention relates generally to a fusion protein that when displayed on a cell can convert a negative signal into a positive signal in the cell. The fusion protein is a chimeric protein in that the protein comprises at least two domains, wherein the first domain is a polypeptide that is associated with a negative signal and the second domain is a polypeptide that is associated with a positive signal. Thus, the invention encompasses switch receptors that are able to switch negative signals to positive signals for enhancement of an immune response.
    Type: Grant
    Filed: July 27, 2012
    Date of Patent: April 20, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Yangbing Zhao
  • Patent number: 10888613
    Abstract: The present invention relates generally to immunotherapy for preventing HIV infection in HIV-negative individuals. In particular, the methods include in vivo and/or ex vivo enrichment of HIV-specific CD4+ T cells.
    Type: Grant
    Filed: January 11, 2017
    Date of Patent: January 12, 2021
    Assignee: American Gene Technologies International Inc.
    Inventors: Charles David Pauza, Haishan Li, Tyler Lahusen
  • Patent number: 10801041
    Abstract: The present invention relates generally to a gene expression system utilizing an alphavirus replicon and T7 promoter. The system is capable of expressing proteins in the cell cytoplasm without integrating the gene of interest into the genome of a host cell. The invention has a wide range of applications such as producing induced pluripotent cells and vaccines against pathogens and cancers.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: October 13, 2020
    Assignee: Orbis Health Solutions, LLC
    Inventor: Thomas E. Wagner
  • Patent number: 10738323
    Abstract: Described herein are reprogramming techniques allowing for production of mammary-derived iPSCs (“m-iPSCs”). The m-iPSCs described herein exhibit all the hallmarks of stem cell identity including round cluster, bright colony morphology, clonal expansion, and pluripotent marker expression (alkaline phosphatase expression, Oct-4, nanog, etc.) Further refined techniques allow for generation of m-iPSCs under essentially defined conditions.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: August 11, 2020
    Assignee: Cedars-Sinai Medical Center
    Inventors: Xiaojiang Cui, Sareen Dhruv, Loren A. Ornelas
  • Patent number: 10729785
    Abstract: The present invention relates to particles comprising protamine, RNA and at least one endosome destabilizing agent, to methods of their production and to pharmaceutical compositions or kits containing the particles. It further relates to particles comprising protamine and RNA for use in methods of treatment or prevention of diseases and to kits comprising such particles together with at least one endosome destabilizing agent.
    Type: Grant
    Filed: May 19, 2014
    Date of Patent: August 4, 2020
    Assignee: BioNTech SE
    Inventor: Steve Pascolo